Increased ILC2 is known to promote collagen deposition, ECM remodeling, fibroblast activation and other processes that promote lung fibrosis, whereas it has been shown that SCFAs can inhibit ILC2 proliferation and inhibit lung fibrosis through FFAR2-independent mechanism (Sepahi et al., 2021). Here, FFAR2 is linked to pulmonary fibrosis.